HC Wainwright Has Optimistic Outlook of RLAY Q2 Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for Relay Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.49) per share for the quarter, up from their prior forecast of ($0.53). HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($1.92) EPS.

A number of other equities research analysts have also recently weighed in on RLAY. Guggenheim cut their price objective on shares of Relay Therapeutics from $30.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group dropped their price target on shares of Relay Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Stifel Nicolaus dropped their price target on shares of Relay Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Finally, Wells Fargo & Company began coverage on shares of Relay Therapeutics in a research report on Thursday, April 17th. They issued an “equal weight” rating and a $4.00 price target on the stock. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.67.

Relay Therapeutics Stock Up 3.7%

Shares of NASDAQ RLAY opened at $3.11 on Monday. Relay Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $10.72. The firm’s 50-day simple moving average is $2.92 and its 200 day simple moving average is $4.01. The stock has a market cap of $533.19 million, a P/E ratio of -1.19 and a beta of 1.65.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.04. The company had revenue of $7.68 million for the quarter, compared to the consensus estimate of $0.01 million. During the same quarter in the prior year, the firm earned ($0.62) earnings per share. Relay Therapeutics’s revenue for the quarter was down 23.0% compared to the same quarter last year.

Insiders Place Their Bets

In other Relay Therapeutics news, CEO Sanjiv Patel sold 75,324 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $3.70, for a total transaction of $278,698.80. Following the sale, the chief executive officer now owns 883,089 shares in the company, valued at approximately $3,267,429.30. The trade was a 7.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Thomas Catinazzo sold 12,943 shares of the business’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $3.00, for a total value of $38,829.00. Following the sale, the chief financial officer now owns 355,376 shares in the company, valued at approximately $1,066,128. The trade was a 3.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 169,644 shares of company stock worth $559,679. Company insiders own 4.87% of the company’s stock.

Institutional Trading of Relay Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its stake in Relay Therapeutics by 118.4% during the 3rd quarter. Barclays PLC now owns 251,819 shares of the company’s stock valued at $1,783,000 after acquiring an additional 136,541 shares in the last quarter. Franklin Resources Inc. grew its stake in Relay Therapeutics by 3,883.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,396,842 shares of the company’s stock valued at $9,429,000 after acquiring an additional 1,361,779 shares in the last quarter. SG Americas Securities LLC grew its stake in Relay Therapeutics by 40.8% during the 4th quarter. SG Americas Securities LLC now owns 77,557 shares of the company’s stock valued at $320,000 after acquiring an additional 22,473 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Relay Therapeutics by 37.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,491 shares of the company’s stock valued at $146,000 after acquiring an additional 9,740 shares in the last quarter. Finally, Savant Capital LLC purchased a new position in Relay Therapeutics during the 4th quarter valued at about $120,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.